Physician profile
Andrew Melson
NPI 1336568146
$6,862.17
in general payments reported to CMS, 2019-2025
16 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Neuro-Ophthalmology provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $266 · 2021: $720 · 2022: $2,746 · 2023: $972 · 2024: $705 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,474.35 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $1,500.72 | 2019-2025 | Clareon, Unity, Centurion |
| Merz Pharmaceuticals, LLC | $661.52 | 2021-2025 | Xeomin |
| Abbvie INC. | $433.31 | 2022-2025 | |
| Amgen INC. | $426.12 | 2024-2025 | Tepezza, Uplizna |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $325.38 | 2019 | |
| Allergan, INC. | $273.11 | 2019-2022 | |
| Merz North America, INC. | $124.22 | 2019-2020 | |
| Glaukos Corporation | $123.65 | 2019 | |
| Alexion Pharmaceuticals, INC. | $119.85 | 2019-2025 | Ultomiris |
| Ocular Therapeutix, INC. | $102.97 | 2021-2025 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $92.92 | 2021 | |
| Mallinckrodt Hospital Products INC. | $65.21 | 2024 | Acthar |
| Catalyst Pharmaceuticals, INC. | $62.47 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $52.50 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iridex Corporation | $23.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Melson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.